Skip to Content

Atripla (efavirenz / emtricitabine / tenofovir) and Alcohol/Food Interactions

There are 3 alcohol/food/lifestyle interactions with Atripla (efavirenz / emtricitabine / tenofovir) which include:

Moderate

efavirenz food

Moderate Food Interaction

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Administration with food increases the plasma concentrations of efavirenz and may increase the frequency of adverse reactions. According to the product labeling, administration of efavirenz capsules (600 mg single dose) with a high-fat/high-caloric meal (894 kcal, 54 g fat, 54% calories from fat) or a reduced-fat/normal-caloric meal (440 kcal, 2 g fat, 4% calories from fat) was associated with mean increases of 39% and 51% in efavirenz peak plasma concentration (Cmax) and 22% and 17% in systemic exposure (AUC), respectively, compared to administration under fasted conditions. For efavirenz tablets, administration of a single 600 mg dose with a high-fat/high-caloric meal (approximately 1000 kcal, 500-600 kcal from fat) resulted in a 79% increase in mean Cmax and a 28% increase in mean AUC of efavirenz relative to administration under fasted conditions.

MANAGEMENT: Efavirenz should be taken on an empty stomach, preferably at bedtime. Dosing at bedtime may improve the tolerability of nervous system symptoms such as dizziness, insomnia, impaired concentration, somnolence, abnormal dreams and hallucinations, although they often resolve on their own after the first 2 to 4 weeks of therapy . Patients should be advised of the potential for additive central nervous system effects when efavirenz is used concomitantly with alcohol or psychoactive drugs, and to avoid driving or operating hazardous machinery until they know how the medication affects them.

References

  1. "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals, Wilmington, DE.
Minor

tenofovir food

Minor Food Interaction

Information for this minor interaction is available on the professional version.

Moderate

High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)

Moderate Potential Hazard, Moderate plausibility

efavirenz - cholesterol

Increases in total cholesterol and triglycerides have resulted during treatment with efavirenz. Lipid levels monitoring should be performed before starting treatment and at periodic intervals during therapy.

References

  1. "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals, Wilmington, DE.

Atripla (efavirenz / emtricitabine / tenofovir) drug interactions

There are 763 drug interactions with Atripla (efavirenz / emtricitabine / tenofovir)

Atripla (efavirenz / emtricitabine / tenofovir) disease interactions

There are 12 disease interactions with Atripla (efavirenz / emtricitabine / tenofovir) which include:

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.